Hopefully we close with a continuation candle; this is

New Post Public Reply Private Reply Replies (0) Message Board
joey68
245
Hopefully we close with a continuation candle; this is where we close slightly lower than the high of the day. This makes it easier for there to be another run the next day.

Notice the previous candles are continuation candles.

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nutromics Welcomes Plaxco: Strategic Tech Leap Forward

Updated Category News Views 2

Professor Plaxco’s Dynamic Role at Nutromics Some folks start their day with breakfast and coffee, but Nutromics is grabbing headlines by introducing Professor Kevin Plaxco as the new Chief Scientific Officer. This strategic shift, made public on September 7, 2026, signals Nutromics’ ambition to amplify its DNA-based sensing footprint. As they gear up to launch their...

Continue Reading
AI and Workforce Transformation: Zellis Connect 2026

Updated Category News Views 0

AI Transformation: Hard Reality or Strategic Opportunity? The future of work. That’s what everyone’s buzzing about lately, isn’t it? AI poised to shake every nook and cranny. You're either riding the wave or getting crushed by it. It’s no longer some distant prospect—the challenge is right here, now. Come September 23, Zellis Connect 2026 is plunging headfirst...

Continue Reading
53% of European Telecom Users Eye Provider Switch

Updated Category News Views 3

Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...

Continue Reading
Hyundai and UEFA: Kicking Off a Game-Changing Deal

Updated Category News Views 3

Hyundai Drives Into Europe's Football Arena Football fever just turned electric with Hyundai allying itself with the UEFA Champions League. We're not talking about sidelines. We're smack dab in the center field of a multi-year partnership starting with the 2026/27 season. Folks, if you think this is just Hyundai shaking hands for brand exposure, think again. This is...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 2

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
D-Wave Hit with Legal Scrutiny After Disappointing Q2

Updated Category News Views 4

D-Wave Quantum Under Legal Microscope Alright, folks, let's dive headfirst into some dicey financial waters with D-Wave Quantum Inc. (NASDAQ: QBTS). This quantum computing company is finding itself in a bit of a pickle following some rough second-quarter results that left investors scratching their heads. If you bought into the hype and are feeling the sting in your...

Continue Reading
Global Movement Urges Dr. Hak Ja Han's Release

Updated Category News Views 3

Under the shadows of Manhattan's skyline, something more than a regular service took shape. The New Yorker Hotel hosted an impassioned gathering of the Family Federation for World Peace and Unification. These folks weren't just saying their prayers; they were making a call—loud and resonant—for the release of Dr. Hak Ja Han. The Power of Collective Voices Gathering in...

Continue Reading
WEPSEA 2026 Propels Southeast Asia's Packaging Leap

Updated Category News Views 2

Revolution in Packaging: Southeast Asia Steps Up Get ready for a wake-up call in the world of packaging, folks; the Southeast Asian market is taking a sharp turn toward sustainability and technological advancement, as highlighted by WEPSEA 2026's recent wrap-up in Shanghai. Far from a mere exhibition, this gathering served as the crucible for change, where old-school...

Continue Reading
AION UT Sets New Safety Standard in Euro NCAP 2026

Updated Category News Views 1

The New Gold Standard in Safety for Small EVs Hop into your favorite auto forum and you'll hear more than a buzz—it's a full-blown ruckus. The reason? GAC’s AION UT just nabbed a 2026 Euro NCAP Five-Star Safety Rating. Now, this isn’t just another accolade in a crowded trophy room; it’s a statement, a seismic shift in how small electric vehicles stack up in terms...

Continue Reading
Sky Labs' CART Monitor Advances BP Monitoring Tech

Updated Category News Views 0

Cuffless BP Monitoring: Changing the Game for AF and HF Ever thought a finger ring could revolutionize blood pressure monitoring? Well, welcome to the future—Sky Labs' ring-type CART monitor has just rocked the scene at the ESC Congress 2026 in Munich. This isn't sci-fi, folks; it's where health tech meets reality, and it's shaking the very foundations of how we manage...

Continue Reading

Top 5 Most Recently Viewed Articles

Lynkwell Boosts Growth with Strategic Investments in North America

Updated Category News Views 191

Lynkwell Amplifies Growth Plans for North American Expansion Lynkwell, a leading player in energy infrastructure, is set to embark on an exciting journey into 2025. With a focus on meeting the growing demands of the evolving electric vehicle (EV) market, Lynkwell is making significant investments to enhance its capabilities and expand its footprint across North America....

Continue Reading
Understanding the Recent Private Student Loan Trends and Insights

Updated Category News Views 197

Overview of Recent Trends in Private Student Loans In the recent semi-annual Private Student Loan Report released by Enterval Analytics, insights into the current status of private student loans reveal a stable repayment landscape. Since Enterval focuses on the private student loan market, their findings shed light on how borrowers are adapting their financial strategies...

Continue Reading
StemCyte's Groundbreaking RMAT Designation for Long COVID-19

Updated Category News Views 63

StemCyte's Major Achievement in Cord Blood Therapy StemCyte has made significant strides in regenerative medicine, specifically with its Hematopoietic Progenitor Cell (HPC) Cord Blood therapy. The company recently announced that it has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) aimed at treating...

Continue Reading
Novo Nordisk Restructures to Combat Rising Competition

Updated Category News Views 214

Novo Nordisk's Significant Job Cuts Novo Nordisk, a leading pharmaceutical company in diabetes care, has announced a major workforce reduction, cutting 9,000 jobs, which amounts to about 11.5% of its employees. This decision reflects the intense market pressure the company faces from its competitor, Eli Lilly. Restructuring for Financial Efficiency The restructuring...

Continue Reading
One Helix: The Innovative Research Hub Transforming Life Sciences

Updated Category News Views 169

Elevating Research with One Helix One Helix emerges as a landmark project in life sciences, representing a new era of innovation and sustainable architecture. Located within a prominent university medical center, this facility is not just a building; it is a commitment to fostering scientific advancements. Completely leased to AstraZeneca, One Helix is designed to elevate...

Continue Reading